for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ビジネス

BVTV: Moderna’s $94 bln hope

The biotechnology firm turned cutting-edge science into a best-selling product in two years. Robert Cyran explains how its valuation is less based on its Covid-19 vaccine than faith it can do this again repeatedly – and how competition might be a problem.

最新のビデオ
世界のこぼれ話
テクノロジー

ビジネス

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up